(Total Views: 501)
Posted On: 09/29/2022 5:36:30 AM
Post# of 148903
Re Covid LH, Ohm wrote,
I still think that Covid LH is uncomfortably protean to pin down. In the earlier trial, 24 symptoms were outlined, and success against them measured. Some were vague, like anxiety and difficulty in concentration. (Everyone who feels one of these, raise your hands! Anyone over 65 here with joint swelling?) Leron had success in 18 of them. So obviously it works with most people in most indications, but is this the kind of open-and-shut data that gets us approval from an FDA that is clearly not willing to give Leron the benefit of the doubt?
With that number of symptoms spread unevenly over the population of the suffering, the trial would have to be massive to fully test all of the symptoms.
It sounded to me as if they are focusing on easy-to-measure indications (cancer, for example) rather than the shifting, wishy-washy disease of widely-varying severities that is Covid LH.
There's also the question of price. If a patient has colorectal cancer, an expensive drug is certainly in order. But if you have runny nose, fatigue, or cough, how much do you want to spend on a drug to help you? I.e., go for a market where it's okay to charge a substantial amount. Let's make some dough.
I wish some partner would come along and pay for LH testing. That would be swell. But I'm okay with focusing on the more narrow, sharper-edged indications where success is measurable and the spending per patient can be high.
Quote:
With the similar symptomology the FDA ME/CFS guidelines could be used for designing the protocol.
I still think that Covid LH is uncomfortably protean to pin down. In the earlier trial, 24 symptoms were outlined, and success against them measured. Some were vague, like anxiety and difficulty in concentration. (Everyone who feels one of these, raise your hands! Anyone over 65 here with joint swelling?) Leron had success in 18 of them. So obviously it works with most people in most indications, but is this the kind of open-and-shut data that gets us approval from an FDA that is clearly not willing to give Leron the benefit of the doubt?
With that number of symptoms spread unevenly over the population of the suffering, the trial would have to be massive to fully test all of the symptoms.
It sounded to me as if they are focusing on easy-to-measure indications (cancer, for example) rather than the shifting, wishy-washy disease of widely-varying severities that is Covid LH.
There's also the question of price. If a patient has colorectal cancer, an expensive drug is certainly in order. But if you have runny nose, fatigue, or cough, how much do you want to spend on a drug to help you? I.e., go for a market where it's okay to charge a substantial amount. Let's make some dough.
I wish some partner would come along and pay for LH testing. That would be swell. But I'm okay with focusing on the more narrow, sharper-edged indications where success is measurable and the spending per patient can be high.
(5)
(0)Scroll down for more posts ▼
